Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

WBF-038

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anatomic Stage 0 Breast Cancer AJCC V8Recruiting

Anatomic Stage 0 Breast Cancer AJCC V8Phase 2

Recruiting

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Anatomic Stage 0 Breast Cancer AJCC V8

NCT07044310

Clinical

Trials by Indication[1]

Anatomic Stage 0 Breast Cancer AJCC v81 trial

Phase 2 Trial of 5-Strain Probiotic Formulation in Hormone Receptor-Positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Recruiting·MMayo Clinic·Phase 2·NCT07044310·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for WBF-038. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WBF-038 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WBF-038. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMayo Clinic

Related News